- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05377996
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This first-in-human (FIH) study will test the safety, side effects, and antitumor activity of a drug called Emi-Le ((Emiltatug Ledadotin, formerly XMT-1660). A side effect is anything a drug does to the body besides treating the disease.
Participants in the study will have cancer that has come back after a period of time during which the cancer could not be detected (recurrent), spread in the body near where it started (advanced) or spread through the body (metastatic).
The study will have three parts. The first part called Dose Escalation, will find out how much Emi-Le should be given to participants. The second part called Dose Expansion, will use the dose found in the first part to find out how safe Emi-Le is and if it works to treat solid tumors. The third part, the Phase 2 part of the trial, called EMBLEM-1, will find out if Emi-Le works to treat aggressive Adenoid Cystic Carcinoma and continue to check how safe Emi-Le is.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Day One Clinical Trials Information
- Phone Number: 1-650-484-0899
- Email: clinicaltrials@dayonebio.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic Comprehensive Cancer Center
-
Principal Investigator:
- Felipe Batalini, MD
-
Contact:
- Felipe Batalini, MD
-
-
California
-
Orange, California, United States, 92868
- Recruiting
- UC Irvine Health-Chao Family Comprehensive Cancer Center
-
Contact:
- Ritesh Parajuli
-
Principal Investigator:
- Ritesh Parajuli
-
San Francisco, California, United States, 94158
- Recruiting
- UCSF Helen Diller Family Comprehensive Cancer Center
-
Principal Investigator:
- Laura Huppert, MD
-
Contact:
- Laura Huppert, MD
-
Santa Monica, California, United States, 90404
- Recruiting
- UCLA David Geffen School of Medicine, Division of Hematology/Oncology
-
Contact:
- Nicholas McAndrew, MD
-
Principal Investigator:
- Nicholas McAndrew, MD
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic - Jacksonville
-
Principal Investigator:
- Pooja Advani, MD
-
Contact:
- Pooja Advani, MD
-
Sarasota, Florida, United States, 34232
- Recruiting
- Florida Cancer Specialists
-
Contact:
- Judy Wang
-
Principal Investigator:
- Judy Wang
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Hyo Han, MD
-
Principal Investigator:
- Hyo Han, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute, Emory University
-
Contact:
- Kevin Kalinsky, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Patricia Robinson, MD
-
Principal Investigator:
- Patricia Robinson, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
Contact:
- Antonio Giordano, MD, PhD
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deaconess Medical Center
-
Contact:
- Gerburg Wulf, MD
-
Principal Investigator:
- Gerburg Wulf, MD
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health Hospital
-
Contact:
- Amy Weise, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic - Rochester
-
Principal Investigator:
- Roberto Leon-Ferre, MD
-
Contact:
- Roberto Leon-Ferre, MD
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Recruiting
- Comprehensive Cancer Centers of Nevada
-
Principal Investigator:
- Liawaty Ho, MD
-
Contact:
- Liawaty Ho, MD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Nour Abuhadra, MD
-
New York, New York, United States, 10016
- Recruiting
- New York University Langone Health
-
Contact:
- Nancy Chan, MD
-
New York, New York, United States, 10029
- Recruiting
- Ichan School of Medicine at Mount Sinai
-
Contact:
- Amy Tiersten
-
Principal Investigator:
- Amy Tiersten
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- Stephenson Cancer Center Oklahoma University Health
-
Principal Investigator:
- Debra Richardson, MD
-
Contact:
- Debra Richardson, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Recruiting
- Avera Cancer Institute
-
Contact:
- David C. Starks, MD
-
Principal Investigator:
- David C. Starks, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute (SCRI)
-
Contact:
- Erika P Hamilton, MD
-
-
Texas
-
Dallas, Texas, United States, 75251
- Recruiting
- Texas Oncology, P.A.
-
Principal Investigator:
- Joyce O'Shaughnessy, MD
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson
-
Principal Investigator:
- Funda Meric-Bernstam
-
Contact:
- Funda Meric-Bernstam
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute
-
Contact:
- Kristen Kelley, MD
-
Principal Investigator:
- Kristen Kelley, MD
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- NEXT Oncology Virginia
-
Contact:
- Alex Spira, MD, PhD
-
-
Washington
-
Seattle, Washington, United States, 09109
- Recruiting
- Fred Hutchinson Cancer Center
-
Contact:
- Jennifer Specht, MD
-
Spokane, Washington, United States, 99208
- Recruiting
- Summit Cancer Centers
-
Contact:
- Arvind Chaudhry, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Recurrent or advanced solid tumor and has disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participants in DES must have at least one measurable disease (target) lesion as defined by RECIST version 1.1.
- Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to Cycle 1 Day 1
Brain magnetic resonance imaging (MRI) during the Screening period unless obtained within 30 days prior to Screening (based on standard clinical care), if they meet either of the following criteria:
- All participants with TNBC
- Participants with a history of brain metastases or with neurologic symptoms or signs suspicious for brain metastases.
Exclusion Criteria:
- Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.
- Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy to the chest within 3 months of starting study treatment or to other anatomic sites within 14 days of starting study treatment.
- Diagnosis of additional malignancy that required active treatment (including surgery, systemic therapy, and radiation) within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.
- Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.
- Prior B7-H4 targeted treatment.
- History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases.
- Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could increase the risk of serious adverse events (SAEs) or interfere with per-protocol evaluations, in the judgment of either the Sponsor or the Investigator.
- Clinically significant cardiovascular disease
- Active keratitis (inflammation of the cornea of the eye)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Emi-Le
Single arm Emi-Le alone (monotherapy)
|
Emi-Le will be administered through a vein in your arm or port catheter (intravenously)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation)
Time Frame: 17 months
|
Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Emi-Le
|
17 months
|
|
Incidence of adverse events (Dose Escalation and Dose Expansion)
Time Frame: 3 years
|
Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose
|
3 years
|
|
Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1)
Time Frame: approximately 3 years
|
The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
|
approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR) (Dose Escalation)
Time Frame: Up to approximately 3 years
|
The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
|
Up to approximately 3 years
|
|
Duration of response (DOR) (Dose Escalation, Dose Expansion, and EMBLEM-1)
Time Frame: Up to approximately 3 years
|
The time from when response criteria are first met until disease progression or death in participants who achieve a complete or partial response
|
Up to approximately 3 years
|
|
Maximum observed plasma concentration of Emi-Le and payload (Cmax) (Dose Escalation and Dose Expansion)
Time Frame: Up to approximately 3 years
|
Cmax is the maximum concentration determined from the measured concentrations in plasma
|
Up to approximately 3 years
|
|
Area under the concentration-time curve of Emi-Le and payload (AUC) (Dose Escalation and Dose Expansion)
Time Frame: Up to approximately 3 years
|
Area under the concentration-time curve for the last measurable concentration (AUC0-last) will be assessed as data permit
|
Up to approximately 3 years
|
|
Antidrug antibodies (ADAs) and neutralizing antibodies (NAbs) (Dose Escalation, Dose Expansion, and EMBLEM-1)
Time Frame: Up to approximately 3 years
|
Assess the development of ADAs and NAbs to Emi-Le
|
Up to approximately 3 years
|
|
Assess the overall survival (OS) of patients treated with Emi-Le (Dose Escalation, Dose Expansion, and EMBLEM-1)
Time Frame: Up to approximately 3 years
|
The time from the date of first dose of study treatment to the date of death due to any cause
|
Up to approximately 3 years
|
|
Incidence of adverse events (EMBLEM-1)
Time Frame: 3 years
|
Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose
|
3 years
|
|
Progression-free survival (PFS) (EMBLEM-1)
Time Frame: Up to approximately 3 years
|
The time from the date of first dose of study treatment until the first date at which disease progression is objectively documented or date of death due to any cause, whichever occurs first
|
Up to approximately 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Robert Burger, MD, Day One Biopharmaceuticals, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Uterine Diseases
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Skin Diseases
- Breast Diseases
- Carcinoma
- Uterine Neoplasms
- Fallopian Tube Diseases
- Skin and Connective Tissue Diseases
- Ovarian Neoplasms
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Carcinoma, Adenoid Cystic
Other Study ID Numbers
- MER-XMT-1660-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.